NEWS Elypta’s urine test shows game-changing potential in kidney cancer follow-up The Swedish company pioneering metabolism-based cancer diagnostics, is proud to announce that findings from the international AURORAX-0087A (AUR87A) study, the largest diagnostics study ever conducted on the most common type of kidney cancer, were presented in a Plenary Game Changer Session at the 2025 European Association of Urology Congress. The intermediary results show that the test correctly identified 90% of patients with recurrent cancer. Read more: https://lnkd.in/dU2XxVwh Congratulations Karl Bergman #healthtech #innovation #oncology #kidneycancer #cancer #wearenina
